- Home
- AZTR vs SGLY Comparison
AZTR vs SGLY Comparison
Compare AZTR & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTR
- SGLY
- Stock Information
- Founded
- AZTR 2014
- SGLY 2001
- Country
- AZTR United States
- SGLY United States
- Employees
- AZTR N/A
- SGLY N/A
- Industry
- AZTR Biotechnology: Pharmaceutical Preparations
- SGLY
- Sector
- AZTR Health Care
- SGLY
- Exchange
- AZTR Nasdaq
- SGLY Nasdaq
- Market Cap
- AZTR 4.2M
- SGLY 3.4M
- IPO Year
- AZTR 2023
- SGLY 2008
- Fundamental
- Price
- AZTR $0.34
- SGLY $0.62
- Analyst Decision
- AZTR Strong Buy
- SGLY
- Analyst Count
- AZTR 1
- SGLY 0
- Target Price
- AZTR $4.00
- SGLY N/A
- AVG Volume (30 Days)
- AZTR 2.8M
- SGLY 176.2K
- Earning Date
- AZTR 11-12-2025
- SGLY 11-14-2025
- Dividend Yield
- AZTR N/A
- SGLY N/A
- EPS Growth
- AZTR N/A
- SGLY N/A
- EPS
- AZTR N/A
- SGLY N/A
- Revenue
- AZTR N/A
- SGLY $1,619,679.00
- Revenue This Year
- AZTR N/A
- SGLY N/A
- Revenue Next Year
- AZTR N/A
- SGLY N/A
- P/E Ratio
- AZTR N/A
- SGLY N/A
- Revenue Growth
- AZTR N/A
- SGLY N/A
- 52 Week Low
- AZTR $0.32
- SGLY $0.54
- 52 Week High
- AZTR $4.33
- SGLY $5.49
- Technical
- Relative Strength Index (RSI)
- AZTR 29.98
- SGLY 42.31
- Support Level
- AZTR $0.32
- SGLY $0.56
- Resistance Level
- AZTR $0.43
- SGLY $0.85
- Average True Range (ATR)
- AZTR 0.07
- SGLY 0.08
- MACD
- AZTR -0.01
- SGLY 0.02
- Stochastic Oscillator
- AZTR 3.02
- SGLY 19.08
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.